Zentalis Pharmaceuticals Llc (ZNTL)

Currency in USD
1.59
+0.11(+7.43%)
Closed·
1.56-0.03(-1.89%)
·
ZNTL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ZNTL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.501.70
52 wk Range
1.015.44
Key Statistics
Prev. Close
1.48
Open
1.5
Day's Range
1.5-1.7
52 wk Range
1.01-5.44
Volume
1.48M
Average Volume (3m)
944.05K
1-Year Change
-50.31%
Book Value / Share
3.81
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZNTL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.19
Upside
+289.15%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Zentalis Pharmaceuticals Llc Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Compare ZNTL to Peers and Sector

Metrics to compare
ZNTL
Peers
Sector
Relationship
P/E Ratio
−0.7x−0.5x−0.5x
PEG Ratio
−0.04−0.020.00
Price/Book
0.4x2.8x2.6x
Price / LTM Sales
4.3x6.5x3.3x
Upside (Analyst Target)
245.9%309.8%40.3%
Fair Value Upside
Unlock8.4%5.1%Unlock

Analyst Ratings

4 Buy
5 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.19
(+289.15% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.37 / -0.54
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ZNTL Income Statement

People Also Watch

3.63
ALT
-1.36%
5.56
REPL
+3.93%
21.81
SRPT
+7.44%
2.53
INMB
+3.27%
3.05
RCKT
+0.66%

FAQ

What Stock Exchange Does Zentalis Pharma Trade On?

Zentalis Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Zentalis Pharma?

The stock symbol for Zentalis Pharma is "ZNTL."

What Is the Zentalis Pharma Market Cap?

As of today, Zentalis Pharma market cap is 114.70M.

What Is Zentalis Pharma's Earnings Per Share (TTM)?

The Zentalis Pharma EPS (TTM) is -2.28.

When Is the Next Zentalis Pharma Earnings Date?

Zentalis Pharma will release its next earnings report on 02 Nov 2025.

From a Technical Analysis Perspective, Is ZNTL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Zentalis Pharma Stock Split?

Zentalis Pharma has split 0 times.

How Many Employees Does Zentalis Pharma Have?

Zentalis Pharma has 166 employees.

What is the current trading status of Zentalis Pharma (ZNTL)?

As of 16 Aug 2025, Zentalis Pharma (ZNTL) is trading at a price of 1.59, with a previous close of 1.48. The stock has fluctuated within a day range of 1.50 to 1.70, while its 52-week range spans from 1.01 to 5.44.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.